A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease. Researchers report that pentamidine might be adapted to counter genetic splicing defects in RNA that lead to type 1 myotonic dystrophy.
A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease. Researchers report that pentamidine might be adapted to counter genetic splicing defects in RNA that lead to type 1 myotonic dystrophy.